Synthesis of steroid bisglucuronide and sulfate glucuronide reference materials: Unearthing neglected treasures of steroid metabolism
作者:Andy Pranata、Christopher C. Fitzgerald、Olha Khymenets、Erin Westley、Natasha J. Anderson、Paul Ma、Oscar J. Pozo、Malcolm D. McLeod
DOI:10.1016/j.steroids.2018.11.017
日期:2019.3
studied by laborious and indirect fractionation, hydrolysis and gas chromatography-mass spectrometry (GC-MS) analysis. Recently, the synthesis and characterisation of steroid bis(sulfate) (aka disulfate or bis-sulfate) reference materials enabled the liquid chromatography-tandem mass spectrometry (LC-MS/MS) study of this metabolite class and the development of a constant ion loss (CIL) scan method for
Methods and systems for determining autism spectrum disorder risk
申请人:Laboratory Corporation of America Holdings
公开号:US10041932B2
公开(公告)日:2018-08-07
In certain embodiments, the invention stems from the discovery that analysis of population distribution curves of metabolite levels in blood can be used to facilitate predicting risk of autism spectrum disorder (ASD) and/or to differentiate between ASD and non-ASD developmental delay (DD) in a subject. In certain aspects, information from assessment of the presence, absence, and/or direction (upper or lower) of a tail effect in a metabolite distribution curve is utilized to predict risk of ASD and/or to differentiate between ASD and DD.
Metabolite biomarkers for diseases associated with the contact activation system
申请人:Takeda Pharmaceutical Company Limited
公开号:US11340237B2
公开(公告)日:2022-05-24
Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
Pregnane steroids for use in the treatment of cns disorders
申请人:Backstrom Torbjorn
公开号:US20050222099A1
公开(公告)日:2005-10-06
Steroid compounds prossessing a hydrogen donor in 3beta position, either in the form of a hydroxy- or a sulfate group, function as efficient blockers of the 3alpha-hydroxy-pregnan-steroid action and thus have utility as therapeutic substances for the prevention and/or treatment of steroid related CNS disorders. Treatment methods based on the administration of these substances are disclosed, and these substances either alone or in combination are also suggested for the manufacture of pharmaceuticals for the treatment of many specific steroid induced CNS disorders.